Keros Therapeutics Inc.

11.44
0.22 (1.96%)
At close: Mar 24, 2025, 3:59 PM
11.40
-0.33%
After-hours: Mar 24, 2025, 07:55 PM EDT
1.96%
Bid 11.11
Market Cap 464.03M
Revenue (ttm) 3.57M
Net Income (ttm) -188.39M
EPS (ttm) -5
PE Ratio (ttm) -2.29
Forward PE -3.11
Analyst Buy
Ask 11.7
Volume 338,468
Avg. Volume (20D) 1,363,174
Open 11.30
Previous Close 11.22
Day's Range 11.29 - 11.62
52-Week Range 9.78 - 72.37
Beta 1.40

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in pat...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 8, 2020
Employees 169
Stock Exchange NASDAQ
Ticker Symbol KROS
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for KROS stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 127.27% from the latest price.

Stock Forecasts
2 months ago
-16.51%
Keros Therapeutics shares are trading lower after ... Unlock content with Pro Subscription
3 months ago
-73.15%
Keros Therapeutics shares are trading lower after the company announced it halted treatment in the 3.0 mg/kg and 4.5 mg/kg arms of its ongoing TROPOS trial due to safety concerns.